Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
暂无分享,去创建一个
S. Park | Tae-You Kim | K. Nishio | S. Morita | Yeul-Hong Kim | T. Satoh | Y. Sakata | S. Rha | Y. Sasaki | Yasuhide Yamada | K. Lee | S. Saitoh | K. Yamaguchi | N. Fuse | Y. Komatsu | H. Yasui | T. Ura | Si-young Kim | M. Munakata | E. Yamamoto | Qingwei Zhang | Jung-mi Kim | Y. Yamada
[1] M. Fukuoka,et al. A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors , 2013, Cancer Chemotherapy and Pharmacology.
[2] A. Wotherspoon,et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial , 2013, The Lancet. Oncology.
[3] Galina Kurteva,et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.
[4] H. Imamura,et al. Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer , 2012, Clinical Cancer Research.
[5] J. Thigpen. Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone , 2012 .
[6] A. Hinke,et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). , 2011, European journal of cancer.
[7] R. Kerbel,et al. Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile , 2011, Cancer biology & therapy.
[8] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[9] M. Frómeta,et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck , 2010, Cancer biology & therapy.
[10] U. Krengel,et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. , 2009, Cancer research.
[11] Yoon-Koo Kang,et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Y. Jeon,et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number , 2008, Histopathology.
[13] Masahiro Takeuchi,et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.
[14] M. Fukuoka,et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status , 2008, British Journal of Cancer.
[15] A. Norman,et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.
[16] Y. Kodera,et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). , 2007, Anticancer research.
[17] J. Ajani,et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Haerting,et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Lage,et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial , 2006, Cancer biology & therapy.
[20] T. Yoshino,et al. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer , 2006, Gastric Cancer.
[21] Elisa Rossi,et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.
[22] J. Koropatnick,et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] I. Choi,et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. , 2004, Japanese journal of clinical oncology.
[24] Suk Woo Nam,et al. BRAF and KRAS mutations in stomach cancer , 2003, Oncogene.
[25] M. Solano,et al. Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer , 2003, Journal of immunotherapy.
[26] J. Rak,et al. Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibody , 2002, International journal of cancer.
[27] U. Haglund,et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[29] U. Haglund,et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] A. Petroianu,et al. Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer , 1993, Cancer.